A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1550188 in Chinese Subjects With Systemic Lupus Erythematosus (SLE)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 14 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 07 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.